Retatrutide vs Survodutide: Triple vs Dual Agonist Comparison for Obesity and MASH

Introduction#

Retatrutide and survodutide represent two next-generation approaches to obesity and metabolic disease treatment that go beyond single-target GLP-1 receptor agonism. Both incorporate glucagon receptor agonism alongside GLP-1 activity, but retatrutide takes this further by adding a third target -- GIP receptor agonism -- making it the first triple-hormone receptor agonist in clinical development.

Retatrutide (LY3437943), developed by Eli Lilly, is a once-weekly injectable GIP/GLP-1/glucagon triple receptor agonist. Phase 3 TRIUMPH-4 demonstrated 28.7% mean weight loss at 68 weeks with the 12 mg dose, confirming the exceptional Phase 2 results (24.2% at 48 weeks; Jastreboff et al., NEJM 2023). Retatrutide has produced the highest weight loss of any single anti-obesity agent in clinical trials.

Survodutide (BI 456906), developed by Boehringer Ingelheim and Zealand Pharma, is a once-weekly injectable GLP-1/glucagon dual receptor agonist. Its Phase 2 obesity trial published in Lancet Diabetes & Endocrinology (2024) showed up to 18.7% weight loss at 46 weeks, while a separate Phase 2 MASH trial demonstrated significant MASH resolution, earning FDA Breakthrough Therapy Designation.

Both remain investigational, with no direct head-to-head comparison. Cross-trial comparisons must be interpreted cautiously due to differences in trial design, patient populations, and dose escalation protocols.

Mechanism of Action Comparison#

Retatrutide#

Retatrutide is a single-molecule triple agonist that simultaneously activates three receptors: GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). This triple mechanism provides complementary metabolic effects: GLP-1R activation suppresses appetite and enhances glucose-dependent insulin secretion; GIPR activation potentiates insulin secretion and may improve fat metabolism and central appetite regulation; and GCGR activation increases hepatic glucose output (balanced by incretin-mediated insulin), promotes energy expenditure through thermogenesis, and enhances hepatic fat oxidation.

The integration of all three pathways is hypothesized to produce synergistic metabolic effects greater than any single or dual agonist combination.

Survodutide#

Survodutide is a dual agonist targeting GLP-1R and GCGR. It omits GIP receptor activity but retains the glucagon component that differentiates it from pure GLP-1 agonists. The glucagon receptor agonism increases energy expenditure and promotes hepatic lipid metabolism, which is particularly relevant for MASH treatment. The GLP-1 component provides appetite suppression and glycemic control.

Key Mechanistic Differences#

Dosing Comparison#

Retatrutide Dosing#

In the Phase 2 trial, retatrutide was administered as once-weekly subcutaneous injections. Dose groups included 0.5 mg, 1 mg (escalation and maintenance), 4 mg (escalation from 2 mg), 8 mg (escalation from 2 to 4 mg), and 12 mg (escalation from 2 to 4 to 8 mg). Treatment duration was 48 weeks. The 12 mg group demonstrated the greatest efficacy.

Survodutide Dosing#

In the Phase 2 obesity trial, survodutide was administered as once-weekly subcutaneous injections at doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg. The trial used a 20-week bi-weekly dose escalation phase followed by a 26-week maintenance phase, for a total of 46 weeks. The 4.8 mg dose showed the greatest efficacy.

Side Effects Comparison#

Retatrutide Side Effects#

GI adverse events were the most common, consistent with the incretin drug class. Nausea occurred in 16-46% of patients depending on dose, diarrhea in 16-26%, and vomiting in 8-22%. Higher doses (8 and 12 mg) had higher GI event rates. Most events were mild to moderate and occurred during dose escalation. Dose-escalation protocols reduced GI intolerance.

Survodutide Side Effects#

GI adverse events occurred in 75% of survodutide recipients versus 42% of placebo recipients. The Phase 2 trial used a relatively rapid bi-weekly dose escalation that may have contributed to higher GI event rates. Nausea, diarrhea, and vomiting were the most common events. Slower titration in Phase 3 trials is expected to improve tolerability.

Research Evidence Comparison#

Retatrutide Research#

The pivotal Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity and demonstrated weight reductions of up to 24.2% at 48 weeks. Phase 3 TRIUMPH-4 confirmed 28.7% weight loss at 68 weeks. A separate Phase 2a trial showed significant liver fat reduction in patients with MASLD/MASH. Additional Phase 3 TRIUMPH readouts are expected in 2026. Evidence level is high based on confirmed Phase 3 data.

Survodutide Research#

Two key Phase 2 trials have been published: the obesity trial (Lancet Diabetes & Endocrinology, 2024) showing 18.7% weight loss at 46 weeks, and the MASH trial (NEJM, 2024) showing 62% MASH resolution at 4.8 mg. Phase 3 SYNCHRONIZE trials for obesity are fully enrolled with results expected H1 2026. Phase 3 LIVERAGE trials for MASH are ongoing. Evidence level is moderate-high with more advanced Phase 3 enrollment than retatrutide.

Key Differences Summary#

• Receptor pharmacology: Retatrutide targets three receptors (GIP + GLP-1 + glucagon) while survodutide targets two (GLP-1 + glucagon). The additional GIP receptor agonism may contribute to retatrutide's greater weight loss.
• Weight loss: Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) versus survodutide's 18.7% at 46 weeks (Phase 2), though cross-trial comparisons are inherently limited.
• MASH: Survodutide has more advanced MASH-specific clinical development with Breakthrough Therapy Designation and dedicated Phase 3 MASH trials.
• Development timeline: Survodutide Phase 3 results are expected sooner (H1 2026 for obesity), potentially reaching market before retatrutide.
• Developer: Retatrutide is developed by Eli Lilly (also maker of tirzepatide), while survodutide is a Boehringer Ingelheim/Zealand Pharma partnership.
• Both drugs: Share GLP-1 and glucagon receptor agonism, once-weekly subcutaneous dosing, similar GI side effect profiles, and investigational status.

Conclusion#

Retatrutide and survodutide both represent significant advances in multi-agonist metabolic therapy, but they take different approaches. Retatrutide's triple-agonist mechanism produced the highest weight loss of any anti-obesity agent in clinical trials (28.7% at 68 weeks in Phase 3 TRIUMPH-4), confirming that the addition of GIP receptor agonism to the GLP-1/glucagon backbone provides substantial incremental benefit. Survodutide, while showing lower weight loss (18.7% in Phase 2), has demonstrated particular promise for MASH treatment with Breakthrough Therapy Designation and dedicated Phase 3 MASH trials.

Neither has been directly compared to the other, and cross-trial comparisons are limited by differences in patient populations, dose escalation, and trial duration. Phase 3 results from both programs will provide a clearer picture of their relative efficacy and safety in larger, more diverse populations. For now, both drugs are positioned as potentially transformative next-generation treatments that could offer advantages over existing single-target GLP-1 agonists.

Further Reading#

• Retatrutide Overview and Research Guide
• Retatrutide Side Effects
• Retatrutide Dosing Protocols
• Survodutide Overview and Research Guide
• Survodutide Side Effects
• Survodutide Dosing Protocols